After review of paclitaxel risks, FDA panel recommends more data - Star Tribune

After review of paclitaxel risks, FDA panel recommends more data  Star Tribune

A panel of doctors and medical experts told the Food and Drug Administration Thursday that regulators should not halt sales of paclitaxel-containing medical ...